GeneDx Holdings
About: GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Employees: 1,000
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
850% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 6
86% more capital invested
Capital invested by funds: $432M [Q2] → $802M (+$370M) [Q3]
83% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 23
58% more funds holding
Funds holding: 86 [Q2] → 136 (+50) [Q3]
6.9% more ownership
Funds ownership: 63.21% [Q2] → 70.11% (+6.9%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 6 (+0) [Q3]
38% less call options, than puts
Call options by funds: $4.35M | Put options by funds: $6.99M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$70
1%
upside
Avg. target
$90
29%
upside
High target
$118
70%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
TD Cowen Dan Brennan 41% 1-year accuracy 12 / 29 met price target | 70%upside $118 | Buy Maintained | 7 Jan 2025 |
Goldman Sachs Matthew Sykes 60% 1-year accuracy 25 / 42 met price target | 1%upside $70 | Neutral Maintained | 30 Oct 2024 |
Wells Fargo Brandon Couillard 44% 1-year accuracy 8 / 18 met price target | 8%upside $75 | Equal-Weight Maintained | 30 Oct 2024 |
Craig-Hallum Bill Bonello 67% 1-year accuracy 4 / 6 met price target | 37%upside $95 | Buy Maintained | 30 Oct 2024 |
Financial journalist opinion
Based on 10 articles about WGS published over the past 30 days
Neutral
Business Wire
3 days ago
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of January 14, 2025, the compensation committee of GeneDx's board of directors granted a total of 69,089 restricted stock units (“RSUs”) to three newly-hired employees as inducements material to each employee entering into employment with GeneDx. The foregoing includes 37,497 RSUs granted to Bryan Dechairo, as an indu.
Positive
Seeking Alpha
5 days ago
GeneDx Holdings: A Phenomenal Comeback With More Room To Run
GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts include the NICU market expansion and pediatric neurology diagnostics, supported by faster turnaround times, non-invasive testing, and EHR integration. Financial improvements include a 44% revenue increase, higher reimbursement rates, and improved gross margins, positioning GeneDx favorably among its peers.
Neutral
Business Wire
1 week ago
GeneDx Announces Preliminary 2024 Financial Results
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported preliminary financial results for the fourth quarter and full year of 2024.
Positive
Investors Business Daily
1 week ago
Outlook For These Biotechs Brightens As FDA Ushers In New Rules For Sector
Biotech stock GeneDx broke out after the FDA issued its first AI rules for medical devices. Globus Medical and GeneDx are in buy zones.
Neutral
Business Wire
1 week ago
GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx launches new telehealth testing pathway to connect parents directly with genetic experts to increase access to exome and genome testing.
Neutral
Business Wire
1 week ago
GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, continues its investment in advancing scientific discovery through understanding gene-disease relationships, contributing to more than 85 peer-reviewed publications in 2024. These contributions, added to GeneDx's years of dedicated research efforts, influenced the broadening of phenotypes, the discovery of new disease mechanisms and new modes of inheritance, and ulti.
Positive
Zacks Investment Research
2 weeks ago
GeneDx Holdings (WGS) Surges 13.2%: Is This an Indication of Further Gains?
GeneDx Holdings (WGS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Positive
Investors Business Daily
2 weeks ago
Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly
Meta Platforms leads five stocks flashing entries as they rebound above key moving averages within consolidations. The post Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly appeared first on Investor's Business Daily.
Positive
Seeking Alpha
2 weeks ago
Best-Performing Stocks Of 2024
Taking a look at the 20 best-performing stocks in 2024 of current Russell 3,000 members.
Neutral
Business Wire
2 weeks ago
GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company's executive leadership team. As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the.
Charts implemented using Lightweight Charts™